Post-vaccinal Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, is a rapidly progressive, invariably fatal neurological disease that attacks the nerve cells responsible for controlling voluntary muscles in the central nervous system, with death usually occurring within two to five years of symptom onset. 

In this case study, a previously asymptomatic 47-year-old male presented with left-sided weakness, declining speech, dysphagia, and recurrent falls for nine months, which began one day after receiving the J&J/Janssen viral vector COVID -19 vaccine. His family history of ALS included his grandmother being diagnosed with it. 

After getting the vaccine, the patient initially experienced painful inflammation at the injection site. Within a week, he began to feel weakness in his left arm and a weak hand grip. Over the following months, this weakness progressed to his entire left side, and he started to experience declining speech, difficulty swallowing, and falling down repeatedly. After a negative MRI of his spine and brain, he was referred to a neurologist and diagnosed with ALS with a pseudobulbar affect after electromyography.

We previously covered post-vaccinal Guillain-Barré syndrome (GBS) that affects the peripheral nervous system and multiple sclerosis (MS) which also impacts the central nervous system similarly to ALS. While MS can cause issues with memory and thought, ALS mostly affects bodily functions.

There are more than 25 genes known to be associated with ALS and about 5–10% of cases of ALS are directly inherited. Overall, first-degree relatives of an individual with ALS have a 1% risk of developing ALS. ALS has an oligogenic mode of inheritance, meaning that mutations in two or more genes are required to cause disease.

C9orf72 (needed for motor neurons and nerve cells) and SOD1 (involved in production of the enzyme copper-zinc superoxide dismutase 1) are the most common genetic causes for ALS1. Mutations in TARDBP, FUS, C9orf72 and other genes can cause ALS as well as related forms of frontotemporal dementia (FTD–ALS) caused by atrophy of the brain's temporal and frontal lobes. 


REFERENCE

Feghali EJ, Challa A, Mahdi M, Acosta E, Jackson J. New-Onset Amyotrophic Lateral Sclerosis in a Patient who Received the J&J/Janssen COVID-19 Vaccine. Kans J Med. 2023 Mar 15; 16:69-70. doi: 10.17161/kjm.vol16.18969. PMID: 36970039; PMCID: PMC10035647.



Comments

Post a Comment

Popular posts from this blog

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

Image
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine.  Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes.  There are ten published case reports about the newly diagnosed ulcerative colitis associate
Read more

COVID in May

Image
Concerns about a potential resurgence of COVID-19 are mounting as summer 2024 approaches.  This is driven by several indicators, including social media posts, healthcare data, and wastewater surveillance across different regions. Our study findings corroborate this trend.  While many forecasters anticipate a surge, others expect a gradual increase through the end of May, and then a decline again around early June. Reports from social media suggest emerging clusters of COVID-19 in Texas, several Canadian provinces, the UK, and on cruises in northern regions such as a Norwegian cruise to Alaska.  Data from Alberta's Respiratory virus dashboard   (total weekly laboratory-confirmed COVID-19 cases) and wastewater surveillance in Calgary indicate an uptick in COVID-19 cases starting April 2024. The most recent statistics from Alberta Health reveal a significant increase in hospitalizations due to COVID-19, with 114 individuals currently hospitalized—an increase of more than 20% over two
Read more

Chronic SARS-CoV-2 Shedding

Image
Chronic viral shedding, a condition where the virus continues to be released from an individual's body long after the initial infection, has been observed in many infectious diseases, including COVID-19.  In such cases, individuals may remain asymptomatic or experience only mild symptoms while the virus persists. It remains detectable in repeated tests over an extended period and can still infect others even in nasal swab is negative (which happens quite often ). This was evident in our study.    Recent research by Conway et al. (2024) highlights the possibility of chronic SARS-CoV-2 infection, extending over several months and potentially years. Other studies have documented prolonged asymptomatic infections and extended viral shedding in moderate to severe beyond hospital discharge. Analysis of sequencing data on UK samples taken between 2 November 2020 and 15 August 2022 lead to estimates that 0.1–0.5% of infections may become persistent with typically rebounding high viral load
Read more